WSJ -- Wockhardt Ltd. (532300.BY) Monday said it has received tentative approval from the U.S. Food & Drug Administration to sell a generic version of Eisai Co.'s (4523.TO) Aricept, a drug for treating Alzheimer’s disease. Tentative approval by the FDA means that, although a product meets all safety, efficacy and manufacturing quality standards required for it to be sold in the U.S., existing patents, or proprietary issues, currently prevent sales. Wockhardt won’t be able to sell its version until it receives final approval from the FDA.
